Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
| Revenue (Most Recent Fiscal Year) | $363.71M |
| Net Income (Most Recent Fiscal Year) | $-913.77M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 51.12 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 188.28 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -264.87% |
| Net Margin (Trailing 12 Months) | -265.93% |
| Return on Equity (Trailing 12 Months) | -446.98% |
| Return on Assets (Trailing 12 Months) | -52.70% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 11.38 |
| Inventory Turnover (Trailing 12 Months) | 0.92 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.42 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.95 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 189.71M |
| Free Float | 184.02M |
| Market Capitalization | $19.48B |
| Average Volume (Last 20 Days) | 4.01M |
| Beta (Past 60 Months) | 0.80 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.00% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |